The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians by Furer, V et al.
ORIGINAL RESEARCH
The Diagnosis and Treatment of Adult Patients
with SAPHO Syndrome: Controversies Revealed
in a Multidisciplinary International Survey
of Physicians
Victoria Furer . Mitsumasa Kishimoto . Shigeyoshi Tsuji .
Yoshinori Taniguchi . Yoko Ishihara . Tetsuya Tomita .
Philip S. Helliwell . Ori Elkayam
Received: August 12, 2020 / Accepted: September 10, 2020 / Published online: September 24, 2020
 The Author(s) 2020
ABSTRACT
Introduction: This study aimed to investigate
the current practice in the diagnosis and treat-
ment of SAPHO syndrome among the
international rheumatology and dermatology
communities.
Methods: We conducted an electronic survey
among the members of the Group for Research
and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA), the Japan Spondyloarthri-
tis, and Israeli Societies of Rheumatology.
Results: A total of 78 physicians participated in
the survey: rheumatologists (83%, n = 65), der-
matologists (11.5%, n = 9), and orthopedics
(3.8%, n = 3). SAPHO was considered a subtype
of spondyloarthritis by 48.7% (n = 38), a sub-
type of psoriatic arthritis by 19.2% (n = 15), a
separate entity by 25.6% (n = 20), and a subtype
of reactive arthritis by 6.4% (n = 5). Palmo-
plantar pustulosis was the most prevalent cuta-
neous manifestation (n = 44, 56.4%) and
anterior chest pain—the most prevalent
osteoarticular manifestation (n = 66, 84.6%).
The majority (84.6%, n = 66) voted for the
update of the present diagnostic criteria by
Khan 1994. Magnetic resonance imaging was
considered the preferred imaging modality for
the diagnosis of SAPHO by 41% (n = 32). Con-
duction of bone biopsy for diagnosis of non-
infectious osteitis was supported only by 10.3%
(n = 8). Patient-reported outcomes were con-
sidered the most appropriate measure for the
assessment of disease activity by 47.4% (n = 37).
The treatment approach was overall similar
among the rheumatology and dermatology
communities, including non-steroidal anti-in-
flammatory drugs, bisphosphonates,
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conventional disease-modifying anti-inflam-
matory drugs, and biologics.
Conclusions: Our study underlines the contro-
versy on diagnosis and treatment of SAPHO
syndrome among specialists in rheumatology
and dermatology and emphasizes an unmet
need for update and validation of diagnostic
criteria and treatment approach.
Keywords: Diagnosis; Psoriatic arthritis;
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Key Summary Points
Controversy on diagnosis and treatment
of synovitis, acne, pustulosis,
hyperostosis, and osteitis (SAPHO)
syndrome is reflected in an international
survey.
There is an unmet need for update and
validation of diagnostic criteria and
treatment approach to SAPHO.
Multidisciplinary international
collaboration is warranted to expand
studies of SAPHO syndrome.
DIGITAL FEATURES
This article is published with digital features to
facilitate understanding of the article. To view
digital features for this article go to https://doi.
org/10.6084/m9.figshare.12933134.
INTRODUCTION
The SAPHO syndrome (acronym for synovitis,
acne, pustulosis, hyperostosis, and osteitis),
introduced by Chamot in 1987, represents a rare
heterogeneous disease mainly targeting the skin
and the skeleton [1]. The true incidence and
prevalence of SAPHO are unknown, as the syn-
drome is commonly under-recognized or mis-
diagnosed. SAPHO mainly affects children and
young adults, often diagnosed as chronic
recurrent multifocal osteomyelitis (CRMO) in
the young population. Clinical manifestations
of SAPHO are variable and share common fea-
tures with psoriatic arthritis (PsA) and spondy-
loarthritis (SpA)-related diseases. The main
cutaneous manifestations include palmoplantar
psoriasis, severe acne, and less commonly,
hidradenitis suppurativa. Musculoskeletal
manifestations typically include a non-infec-
tious osteitis, hyperostosis, and synovitis of the
anterior chest wall, with the sternoclavicular
junction being commonly affected, followed by
the spine, sacroiliac joints, and peripheral non-
erosive arthritis. Skin lesions may precede, fol-
low, or occur simultaneously with the onset of
musculoskeletal manifestations [2, 3]. Several
clinical patterns of SAPHO have been recog-
nized, including a relapsing–remitting or
chronic disease in the majority of cases and
rarely a monophasic disease [4]. Non-infectious
sterile osteitis with subsequent hyperostosis
resulting in osteolytic and osteosclerotic bone
lesions represent a distinct pathological and
radiographic feature of SAPHO [5]. Etiopatho-
genesis of SAPHO is considered multifactorial.
Low virulent pathogens, such as Propionibac-
terium acnes, may trigger an exaggerated
inflammatory response of the bone marrow in
genetically susceptible individuals, leading to a
form of ‘‘reactive osteitis’’ [6].
Diagnostic criteria for SAPHO remain pre-
liminary and lack validation. The first diagnos-
tic criteria proposed by Chamot were based on
the clinical grounds, including a wide spectrum
of clinical features [1], further followed by cri-
teria proposed by Kahn requiring pathological
evidence of osteitis or osteomyelitis for estab-
lishing the diagnosis, with or without typical
skin lesions [7]. The modified criteria proposed
by Hayem, based on an observational cohort of
120 patients with SAPHO, suggested to base the
diagnosis on the combination of typical
osteoarticular and skin manifestations, follow-
ing the exclusion of inflammatory bowel dis-
ease, bone infection, and tumors [8]. To date,
no formal guidelines outlining a diagnostic
approach to SAPHO exist. Bone scintigraphy is
commonly used as first-line imaging in the
systemic evaluation of osteoarticular lesions in
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SAPHO syndrome [9]. In view of advances in
imaging techniques, magnetic resonance imag-
ing (MRI), computerized tomography (CT), and
ultrasonography (US) application of an appro-
priate imaging modality for diagnosis and
monitoring of disease activity is highly needed
in patients with SAPHO, along with avoidance
of unnecessary imaging tests. No specific core
domain set of outcome measures were devel-
oped or applied in SAPHO. Furthermore, there
are no evidence-based treatment algorithms in
SAPHO due to a lack of clinical trials in this rare
medical condition. Treatment choice is based
on retrospective reports and case series. In fact,
a wide spectrum of medications has been used
to treat SAPHO, extrapolated from treatment
approaches to psoriasis, severe acne, PsA, and
SpA. To date, there are no data on long-term
efficacy, adverse events, and outcomes of dif-
ferent treatments in SAPHO [10].
SAPHO is a rare disease involving skin and
rheumatologic manifestations, with a poten-
tially complicated and severe course. Clinical
presentation may pertain to several specialties,
including rheumatology, dermatology, ortho-
pedics, physiotherapists, and pediatricians.
Optimal management of these patients requires
multidisciplinary collaborative care. The Group
for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) is an international
network platform of medical disciplines treating
psoriasis and psoriatic arthritis and recent inter-
est in this condition was reflected in a sympo-
sium on pustular psoriasis and SAPHO during the
recent GRAPPA virtual annual meeting in July
2020 (www.grappanetwork.org). To further
explore current concepts and practice on the
approach and treatment strategies in SAPHO, a
survey was conducted among the members of
GRAPPA as well as the Japanese Sponsyloarthri-
tis and Israeli Societies of Rheumatology, and the
results are presented here.
METHODS
An electronic online survey was conducted
among the members of GRAPPA, Japanese
Spondyloarthritis, and Israeli Societies of
Rheumatology. The questionnaire was
distributed to 703 physicians, including 26
members of the Japanese Spondyloarthritis
Society, 70 members of Israeli Society of
Rheumatology, and 613 GRAPPA members (one
Japanese responder and five Israeli responders
belonged to GRAPPA as well). No selection cri-
teria were applied. The survey took place in 2017,
using a Google Forms platform. The language of
the survey was English. The study, considered as
less than ‘minimal risk research’, was certified as
exempt by the Tel Aviv Sourasky Medical Center
Institutional Review Board (Helsinki Commit-
tee) and participants’ written informed consent
was waived as the participation in the study was
voluntarily and each participant had an option
to fill out the survey anonymously. In the survey,
responders were asked to state their medical
subspecialty and the country of origin. SAPHO-
related questions included the total number of
SAPHO patients under a physician’s care, the
annual number of new SAPHO cases, the most
commonly encountered osteoarticular and skin
manifestations, and preferable imaging modal-
ity for the diagnosis of SAPHO in the clinical
practice. The use of ultrasound in the assessment
of sternoclavicular or other sternal joints and the
performance of bone biopsy in cases of osteitis or
hyperostosis for the diagnosis of SAPHO was
posed. The responders were asked whether the
1994 diagnostic criteria for SAPHO reflected the
characteristics of SAPHO patients in their prac-
tice and whether there was a need for the update
or modification of the SAPHO diagnostic criteria.
Responders’ points of view on the classification
of the SAPHO syndrome to one of the following
diseases’ subgroups: psoriatic arthritis, spondy-
loarthropathy, reactive arthritis, or a separate
independent entity were evaluated. Further,
measures for the assessment of disease activity
were inquired. Survey participants were ques-
tioned about the treatment approach to SAPHO
and whether there was a difference in the treat-
ment approach in patients with psoriasis versus
acne.
RESULTS
A total of 78 physicians completed the survey,
reflecting a response rate of 11.1%. Among the
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responders, there were 63 (80.7%) adult
rheumatologists, two (2.6%) pediatric rheuma-
tologists, eight (10.3%) dermatologists, one
(1.3%) double-board certified rheumatologist
and dermatologist, three (3.8%) orthopedic
surgeons, and one (1.3%) radiologist. There was
a wide geographic representation among the
responders: North America (n = 5) and Canada
(n = 1), Europe (n = 11); Far East: Japan (n = 26),
Korea (n = 1), Singapore (n = 1); Middle East:
Israel (n = 23), Turkey (n = 1), South America
(n = 5), and India (n = 1). Three responders did
not identify their country. Table 1 summarizes
the results of the survey based on the geo-
graphic region. The majority of the responders
(n = 67, 86%) reported experience in the man-
agement of patients with SAPHO. Forty-four
responders reported caring for 1–10 SAPHO
patients, 14 responders reported caring for
11–20 SAPHO patients, and seven responders
reported caring for up to 50 SAPHO patients in
total. The annual incidence of 1–5 SAPHO
cases/year was reported by the majority (n = 61,
78.2%). Eight responders (10.3%), mainly from
Japan, reported an annual incidence of 6–10
cases/year in their practice. Palmoplantar pus-



































































































































































































































































































































































































































































Anti-TNF biologic therapy 75.3





Intra-articular steroid injection 7.8
NSAIDs non-steroidal anti-inflammatory drugs, DMARDs
disease-modifying anti-rheumatic drugs
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Manifestation among all regions (n = 44,
56.4%), with a particularly high prevalence in
Japan (n = 23, 82.1%), followed by acne (n = 20,
25.6%), pustular psoriasis (n = 7, 9%), and
rarely hidradenitis suppurativa (n = 5, 5.1%).
Anterior chest pain and swelling (osteitis,
hyperostosis, and joint inflammation of the
anterior chest bones and joints) was the most
prevalent osteoarticular manifestation (n = 66,
84.6%), followed by peripheral arthritis (n = 5,
6.4%), sacroiliitis (n = 2, 2.6%), and enthesitis
(n = 2, 2.6%). Chronic recurrent multifocal
osteomyelitis (CRMO) was reported by three
responders (3.8%). MRI was considered the
preferred imaging modality for SAPHO diagno-
sis by 41% (n = 32) of the responders, whereas
26.9% (n = 21) preferred bone scan, and 19.2%
(n = 15) voted for computerized tomography
(CT) scan. Four responders (5.1%) reported
using US applied for sternum joints for SAPHO
diagnosis. Regarding the indication for bone
biopsy to confirm the diagnosis of SAPHO in
cases of osteitis or hyperostosis, only 10.3%
(n = 8) supported the conduction of biopsy,
whereas 55% (n = 43) found no need for this
test in the diagnostic work-up of SAPHO. A
third of the responders (34.6%) were uncertain
regarding this item. Whereas 59% (n = 46) sta-
ted that the Khan diagnostic criteria mainly
reflected SAPHO cases in their practice, the vast
majority (84.6%, n = 66) still voted for modifi-
cation and update of these criteria. SAPHO was
considered as a subtype of SpA by 48.7%
(n = 38), a subtype of PsA by 19.2% (n = 15), a
separate entity by 25.6% (n = 20), and reactive
arthritis subtype by 6.4% (n = 5). Patient-re-
ported outcomes, including patient global and
pain assessment (VAS), were considered the
most appropriate measures for assessment of
disease activity by 47.4% (n = 37), followed by
clinical physician disease assessment by 16.7%
(n = 13), Ankylosing Spondylitis Disease Activ-
ity Score (ASDAS) by 10.3% (n = 8), and blood
inflammatory markers by 9% (n = 7). Six (7.7%)
responders suggested a follow-up of disease
activity by US, 2.6% (n = 2) by bone scan, and
one (1.3%) by MRI. Three responders (3.8%)
suggested a combination of clinical, laboratory,
and imaging measures for assessment of disease
activity and follow-up. The list of preferable
medications and treatments used for SAPHO is
presented in Table 2. The question related to the
treatment approach to SAPHO was formulated
as a multiple-choice question, presenting a list
of potential therapeutics. Overall, the treatment
approach was similar among the rheumatology
and dermatology responders. Non-steroidal
anti-inflammatory drugs (NSAIDs) were the first
choice universally listed by most responders
(colchicine was not specifically mentioned),
followed in decreasing order of frequency by
anti-TNFa biologics, conventional DMARDs,
bisphosphonates, other biologics (not specifi-
cally named), and finally antibiotics. Remark-
ably, only Japanese responders (n = 4) suggested
tonsillectomy as an additional mode of treat-
ment. Comparing treatment approaches among
different regions, European and Middle East
responders reported a significantly more com-
mon use of bisphosphonates (63.6%, n = 7 and
62.5%, n = 15, respectively) compared to Japa-
nese responders (n = 11, 39.3%). Whereas
27.3% (n = 3) of European and 17.8% (n = 5) of
Japanese responders reported the use of antibi-
otics, none of the Israeli responders used this
treatment.
DISCUSSION
Our survey provides insight into the current
approach and treatment practices of an inter-
national community of physicians, mainly
rheumatologists and dermatologists, experi-
enced in the care of patients with SAPHO. This
syndrome is not only rare and heterogeneous
but also presents in different subsets around the
globe. SAPHO manifestations in Asian and
Caucasian populations show different charac-
teristics. Asian patients with SAPHO mainly
present with PPP and only rarely with severe
acne or hidradenitis suppurativa. In fact, pus-
tulotic arthro-osteitis (PAO) is the most com-
mon form of SAPHO in the Japanese
population. PAO was first reported by Sonozaki
et al. in 1979 based on a case series of 22 cases
with PPP and anterior chest involvement [11],
further expanded to 53 cases [12]. Histologic
examination of the anterior wall tissues
revealed non-suppurative chronic
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inflammation of the soft tissues around the
sterno-costo-clavicular region or nonspecific
chronic inflammation of bones. Spondylitis,
sacroiliitis, and peripheral non-erosive arthritis
were observed in up to 30% of this cohort. All
patients were HLA-B27 negative. Whether PAO
in Japan is a genetically and clinically distinct
entity or not requires further investigation.
Radiologically, spinal lesions are more common
in Asians versus Caucasians [4, 13–15]. Limited
reports point to a particularly severe form of
SAPHO in the African-American population,
characterized by acne fulminans and
hidradenitis suppurativa [16]. There is a lack of
data on SAPHO characteristics from other geo-
graphic regions. Our survey seems to be unique
representing an insight into the features of
SAPHO among a widespread community of
rheumatologists and dermatologists. In terms of
clinical features, PPP represented the most
common cutaneous manifestation across the
globe, followed by acne in the Middle East and
European communities. Hidradenitis suppura-
tiva was reported only in the North American,
Canadian, and European communities. The
involvement of the anterior chest wall was the
most common osteoarticular manifestation,
consistent with the observational data from
Europe [15] and Japan [14]. The prevalence of
peripheral arthritis, enthesitis, sacroiliitis, and
CRMO was variable in different geographic
regions. The nosology of SAPHO was mainly
viewed as a subtype of SpA, followed by PsA
subtype, except for the South American sub-
group, which categorized SAPHO as a separate
and independent entity. The survey demon-
strated a wide range of opinions regarding the
preferred imaging modality in SAPHO, ranging
from MRI (most commonly applied in North
America, Canada, and the Middle East), CT
(equally applied in the Far East, South America,
and the Middle East), USA (most commonly
applied in Europe), and bone scan (most com-
monly applied in South America). Notably, the
choice of the imaging modality should be
dependent on the stage of the disease, as early
and late radiographic findings significantly dif-
fer. For example, early lesions tend to be
osteodestructive and best demonstrated by MRI
or bone scintigraphy, whereas late lesions tend
to be osteoproliferative, resulting in hyperosto-
sis and sclerosis that are best assessed on CT
scanning [9]. Further, a discussion regarding the
need for bone biopsy in the diagnosis of
SAPHO-related osteitis was demonstrated, with
the majority of responders voting for no need
for biopsy (for example, 100% of European
responders) or being unsure regarding this item.
Consensus for the update of the diagnostic cri-
teria was reached across all regions. Other dis-
cussion points included the measures for disease
assessment and the therapeutic approach.
Limitations of our study relate to the
inherent limitations of the study design as a
survey. Notably, there was a low response rate,
which might be explained by the rarity of
SAPHO syndrome around the globe. In fact,
some of the responders reported no personal
experience with SAPHO patients. Yet, we deci-
ded to include their views on the diagnosis and
treatment of SAPHO, as they reflected the cur-
rent concepts on SAPHO of the corresponding
medical society. A discrepancy in recall accu-
racy of the responders was another inherent
limitation of the survey design. Furthermore,
the questionnaire used in this survey was in
particular constructed for this study, without
prior validation. All the mentioned limitations
might potentially affect the validity of the
study.
CONCLUSIONS
In summary, the results of our survey reflect the
diversity in the current diagnostic and thera-
peutic approach to SAPHO syndrome in clinical
practice. An unmet need for the update, modi-
fication, and validation of the SAPHO diagnos-
tic criteria and setting disease activity measures
was reflected by most of the participants. Future
directions include establishing an international
registry for SAPHO, which will lead to the
development of classification and diagnostic
criteria for SAPHO.
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